If you already have heart disease and are taking a statin to lower cholesterol, adding this special niacin pill with another drug called laropiprant might make your blood sugar harder to control and could even cause you to develop diabetes — about 4 more people out of 100 will have serious blood sugar problems, and 1 more out of 100 will get diagnosed with diabetes over a few years.
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
This claim is based on data from a large, randomized controlled trial (HPS2-THRIVE) that directly measured outcomes in a well-defined population receiving a specific intervention versus placebo. The use of absolute risk differences (percentage points) and median follow-up duration indicates precise reporting from primary data. The effect sizes are reported with appropriate statistical precision, and the causal language is justified by the RCT design. No overstatement is present.
More Accurate Statement
“In adults with atherosclerotic vascular disease on statin therapy, the addition of extended-release niacin (2 g/day) with laropiprant (40 mg/day) increases the absolute risk of serious disturbances in diabetes control by 3.7 percentage points and new diabetes diagnoses by 1.3 percentage points over a median follow-up of 3.9 years, as demonstrated in the HPS2-THRIVE trial.”
Context Details
Domain
medicine
Population
human
Subject
Adults with atherosclerotic vascular disease on statin therapy
Action
increases
Target
the absolute risk of serious disturbances in diabetes control by 3.7 percentage points and new diabetes diagnoses by 1.3 percentage points
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
Effects of extended-release niacin with laropiprant in high-risk patients.
This big study gave people with heart disease niacin and laropiprant along with their statin pills, and found that more of them had serious blood sugar problems or developed diabetes compared to those who got a placebo — exactly as the claim says.